- Year-over-year revenue grows 12%, operating profit up 5%, non-GAAP operating profit up 5%
Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) — ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2022.
Third Quarter 2022 Highlights
All comparisons are to the prior year period
- Revenue increased by 12% to $864.5 million; up 14% on a constant currency basis
- Gross margin contracted 140 bps to 56.8%; non-GAAP gross margin contracted 150 bps to 58.1%
- Income from operations increased 5%; non-GAAP operating profit up 5%
- Diluted earnings per share of $1.22; non-GAAP diluted earnings per share of $1.32
“Our third-quarter results reflect strong performance across our business, resulting in double-digit top-line revenue growth including extraordinary demand in our sleep and respiratory care business segment as well as solid high-single-digit growth in our software-as-a-service segment,” said Mick Farrell, ResMed CEO. “I am proud of our global team’s ability to pivot and drive continued growth while ongoing supply chain disruptions and a competitor’s recall continue to limit our ability to meet the incredible demand for our products. We remain focused on delivering products, software, and services for patients, working closely with our supply chain partners as well as physicians, providers, and beyond, to prioritize care for patients who most need it.
“While the current industry and macroeconomic environment remain uncertain, our long-term strategy allows us to keep our focus on helping 250 million lives in 2025. Our end-market demand from patients and providers remains strong, and our digital health technologies continue to deliver value. We are supporting patients with the world-leading portfolio of sleep apnea therapy, respiratory care therapy, and digital health solutions they need, as we deliver value for all of our customers.”
Financial Results and Operating Metrics
Unaudited; $ in millions, except for per share amounts
| Three Months Ended | |||||||||||||
| March 31, 2022 |
March 31, 2021 |
% Change | Constant Currency (A) |
||||||||||
| Revenue | $ | 864.5 | $ | 768.8 | 12 | % | 14 | % | |||||
| Gross margin (B) | 56.8 | % | 58.2 | % | (2 | ) | |||||||
| Non-GAAP gross margin (B) | 58.1 | % | 59.6 | % | (3 | ) | |||||||
| Selling, general, and administrative expenses | 182.4 | 160.4 | 14 | 17 | |||||||||
| Research and development expenses | 66.8 | 55.9 | 19 | 22 | |||||||||
| Income from operations | 234.3 | 223.4 | 5 | ||||||||||
| Non-GAAP income from operations (B) | 253.0 | 241.8 | 5 | ||||||||||
| Net income (loss) | 179.0 | (78.5 | ) | NM | |||||||||
| Non-GAAP net income (B) | 193.3 | 190.4 | 2 | ||||||||||
| Diluted earnings (loss) per share | $ | 1.22 | $ | (0.54 | ) | NM | |||||||
| Non-GAAP diluted earnings per share (B) | $ | 1.32 | $ | 1.30 | 2 | ||||||||
NM Not meaningful
| Nine Months Ended | |||||||||||||
| March 31, 2022 |
March 31, 2021 |
% Change | Constant Currency (A) |
||||||||||
| Revenue | $ | 2,663.4 | $ | 2,320.7 | 15 | % | 15 | % | |||||
| Gross margin (B) | 56.4 | % | 58.1 | % | (3 | ) | |||||||
| Non-GAAP gross margin (B) | 57.6 | % | 59.8 | % | (4 | ) | |||||||
| Selling, general, and administrative expenses | 544.5 | 488.9 | 11 | 13 | |||||||||
| Research and development expenses | 189.3 | 165.4 | 14 | 15 | |||||||||
| Income from operations | 744.9 | 662.0 | 13 | ||||||||||
| Non-GAAP income from operations (B) | 801.3 | 733.4 | 9 | ||||||||||
| Net income | 584.4 | 279.4 | 109 | ||||||||||
| Non-GAAP net income (B) | 631.5 | 582.2 | 8 | ||||||||||
| Diluted earnings per share | $ | 3.97 | $ | 1.91 | 108 | ||||||||
| Non-GAAP diluted earnings per share (B) | $ | 4.30 | $ | 3.98 | 8 | ||||||||
(A) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted
- Revenue grew by 14 percent on a constant currency basis, driven by increased demand for our sleep and respiratory care devices and increased demand following a recent product recall by one of our competitors.
- Revenue in the U.S., Canada, and Latin America, excluding software-as-a-service, grew by 18 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19.
- Revenue in Europe, Asia, and other markets grew by 11 percent on a constant currency basis, primarily due to the factors discussed above.
- Software-as-a-service revenue increased by 8 percent, due to continued growth in our Durable Medical Equipment category and stabilizing patient flow in out-of-hospital care settings.
- Gross margin decreased by 140 basis points and non-GAAP gross margin decreased by 150 basis points, mainly due to higher freight and manufacturing costs, partially offset by favorable product mix changes and increase in average selling prices.
- Selling, general, and administrative expenses increased by 17 percent on a constant currency basis. SG&A expenses increased to 21.1 percent of revenue in the quarter, compared with 20.9 percent in the same period of the prior year. These changes in SG&A expenses were mainly due to increases in employee-related expenses.
- Income from operations increased by 5 percent and non-GAAP income from operations increased by 5 percent.
- Net income for the quarter was $179.0 million and diluted earnings per share was $1.22. Non-GAAP net income grew by 2 percent and non-GAAP diluted earnings per share grew by 2 percent, predominantly attributable to strong sales, partially offset by higher operating expenses.
- Operating cash flow for the quarter was $117.4 million, compared to net income in the current quarter of $179.0 million and non-GAAP net income of $193.3 million. During the quarter we paid $61.4 million in dividends.
Other Business and Operational Highlights
- Announced appointment of Urvashi Tyagi as new Chief Technology Officer and Bobby Ghoshal transitions to be President of ResMed’s software-as-a-service business segment full-time. Tyagi leads ResMed’s digital health technology team, driving innovation and adoption of world-leading cloud-based digital health platforms and investments in emerging technologies.
- Published 2022 Global Sleep Surveys as part of National Sleep Awareness Week (March 13-19) and World Sleep Day (March 18). The surveys, conducted in the first quarter of the calendar year, asked nearly 25,000 respondents in 12 countries what’s keeping them up at night; the results aim to build awareness of the critical role good sleep plays in physical and mental health.
Dividend program
The ResMed board of directors today declared a quarterly cash dividend of $0.42 per share. The dividend will have a record date of May 12, 2022, payable on June 16, 2022. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 11, 2022, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from May 11, 2022, through May 12, 2022, inclusive.
Webcast details
ResMed will discuss its third-quarter fiscal year 2022 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on ResMed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2022 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13727876. The telephone replay will be available until May 12, 2022.
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital
Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding ResMed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed’s periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.
Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2022 |
March 31, 2021 |
March 31, 2022 |
March 31, 2021 |
||||||||||||
| Net revenue | $ | 864,500 | $ | 768,767 | $ | 2,663,390 | $ | 2,320,722 | |||||||
| Cost of sales | 362,321 | 310,585 | 1,128,314 | 933,021 | |||||||||||
| Amortization of acquired intangibles (1) | 10,982 | 10,924 | 33,271 | 34,066 | |||||||||||
| Restructuring—cost of sales (1) | — | — | — | 5,232 | |||||||||||
| Total cost of sales | $ | 373,303 | $ | 321,509 | $ | 1,161,585 | $ | 972,319 | |||||||
| Gross profit | $ | 491,197 | $ | 447,258 | $ | 1,501,805 | $ | 1,348,403 | |||||||
| Selling, general, and administrative | 182,401 | 160,446 | 544,483 | 488,904 | |||||||||||
| Research and development | 66,801 | 55,941 | 189,258 | 165,409 | |||||||||||
| Amortization of acquired intangibles (1) | 7,730 | 7,445 | 23,175 | 23,377 | |||||||||||
| Restructuring—operating expenses (1) | — | — | — | 8,673 | |||||||||||
| Total operating expenses | $ | 256,932 | $ | 223,832 | $ | 756,916 | $ | 686,363 | |||||||
| Income from operations | 234,265 | 223,426 | 744,889 | 662,040 | |||||||||||
| Other income (expenses), net: | |||||||||||||||
| Interest income (expense), net | $ | (5,462 | ) | $ | (5,823 | ) | $ | (16,770 | ) | $ | (18,341 | ) | |||
| Loss attributable to equity method investments | (2,627 | ) | (4,969 | ) | (5,927 | ) | (9,895 | ) | |||||||
| Gain (loss) on equity investments | (1,735 | ) | 4,666 | (527 | ) | 9,442 | |||||||||
| Other, net | 1,878 | 705 | 729 | 1,205 | |||||||||||
| Total other income (expenses), net | (7,946 | ) | (5,421 | ) | (22,495 | ) | (17,589 | ) | |||||||
| Income before income taxes | $ | 226,319 | $ | 218,005 | $ | 722,394 | $ | 644,451 | |||||||
| Income taxes | 47,307 | 296,486 | 138,018 | 365,046 | |||||||||||
| Net income (loss) | $ | 179,012 | $ | (78,481 | ) | $ | 584,376 | $ | 279,405 | ||||||
| Basic earnings per share | $ | 1.22 | $ | (0.54 | ) | $ | 4.00 | $ | 1.92 | ||||||
| Diluted earnings per share | $ | 1.22 | $ | (0.54 | ) | $ | 3.97 | $ | 1.91 | ||||||
| Non-GAAP diluted earnings per share (1) | $ | 1.32 | $ | 1.30 | $ | 4.30 | $ | 3.98 | |||||||
| Basic shares outstanding | 146,240 | 145,513 | 145,969 | 145,217 | |||||||||||
| Diluted shares outstanding | 146,962 | 145,513 | 147,034 | 146,394 | |||||||||||
(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.
Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)
| March 31, 2022 |
June 30, 2021 |
||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 201,769 | $ | 295,278 | |||
| Accounts receivable, net | 508,580 | 614,292 | |||||
| Inventories | 664,943 | 457,033 | |||||
| Prepayments and other current assets | 329,008 | 208,154 | |||||
| Total current assets | $ | 1,704,300 | $ | 1,574,757 | |||
| Non-current assets: | |||||||
| Property, plant, and equipment, net | $ | 513,250 | $ | 463,490 | |||
| Operating lease right-of-use assets | 141,173 | 128,575 | |||||
| Goodwill and other intangibles, net | 2,302,301 | 2,320,483 | |||||
| Deferred income taxes and other non-current assets | 244,240 | 240,820 | |||||
| Total non-current assets | $ | 3,200,964 | $ | 3,153,368 | |||
| Total assets | $ | 4,905,264 | $ | 4,728,125 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY: | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 149,797 | $ | 138,008 | |||
| Accrued expenses | 326,276 | 320,599 | |||||
| Operating lease liabilities, current | 24,130 | 23,585 | |||||
| Deferred revenue | 112,449 | 109,611 | |||||
| Income taxes payable | 42,646 | 307,963 | |||||
| Short-term debt | 11,967 | 12,000 | |||||
| Total current liabilities | $ | 667,265 | $ | 911,766 | |||
| Non-current liabilities: | |||||||
| Deferred revenue | $ | 94,094 | $ | 91,496 | |||
| Deferred income taxes | 10,711 | 11,319 | |||||
| Operating lease liabilities, non-current | 127,254 | 114,779 | |||||
| Other long-term liabilities | 5,103 | 6,802 | |||||
| Long-term debt | 668,735 | 643,351 | |||||
| Long-term income taxes payable | 53,298 | 62,933 | |||||
| Total non-current liabilities | $ | 959,195 | $ | 930,680 | |||
| Total liabilities | $ | 1,626,460 | $ | 1,842,446 | |||
| STOCKHOLDERS’ EQUITY: | |||||||
| Common stock | $ | 585 | $ | 583 | |||
| Additional paid-in capital | 1,645,453 | 1,622,199 | |||||
| Retained earnings | 3,480,163 | 3,079,640 | |||||
| Treasury stock | (1,623,256 | ) | (1,623,256 | ) | |||
| Accumulated other comprehensive income | (224,141 | ) | (193,487 | ) | |||
| Total stockholders’ equity | $ | 3,278,804 | $ | 2,885,679 | |||
| Total liabilities and stockholders’ equity | $ | 4,905,264 | $ | 4,728,125 | |||
Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)
| Nine months ended | |||||||
| March 31, 2022 |
March 31, 2021 |
||||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 584,376 | $ | 279,405 | |||
| Adjustment to reconcile net income to cash provided by operating activities: | |||||||
| Depreciation and amortization | 122,198 | 120,034 | |||||
| Amortization of right-of-use assets | 26,636 | 25,805 | |||||
| Stock-based compensation costs | 49,265 | 47,032 | |||||
| Loss attributable to equity method investments | 5,927 | 9,895 | |||||
| (Gain) loss on equity investment | 527 | (9,442 | ) | ||||
| Restructuring expenses | — | 8,673 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable, net | 98,158 | (39,899 | ) | ||||
| Inventories, net | (209,476 | ) | (48,393 | ) | |||
| Prepaid expenses, net deferred income taxes and other current assets | (127,977 | ) | (41,036 | ) | |||
| Accounts payable, accrued expenses, income taxes payable and other | (277,973 | ) | 158,119 | ||||
| Net cash (used in) / provided by operating activities | $ | 271,661 | $ | 510,193 | |||
| Cash flows from investing activities: | |||||||
| Purchases of property, plant, and equipment | (106,192 | ) | (74,805 | ) | |||
| Patent registration and acquisition costs | (17,449 | ) | (11,149 | ) | |||
| Business acquisitions, net of cash acquired | (35,915 | ) | (30,704 | ) | |||
| Purchases of investments | (16,614 | ) | (20,038 | ) | |||
| Proceeds from sale of investment | 6,802 | — | |||||
| (Payments) / proceeds on maturity of foreign currency contracts | (5,309 | ) | 26,306 | ||||
| Net cash used in investing activities | $ | (174,677 | ) | $ | (110,390 | ) | |
| Cash flows from financing activities: | |||||||
| Proceeds from issuance of common stock, net | 26,269 | 18,759 | |||||
| Taxes paid related to net share settlement of equity awards | (52,278 | ) | (49,938 | ) | |||
| Payments of business combination contingent consideration | — | (3,500 | ) | ||||
| Proceeds from borrowings, net of borrowing costs | 160,000 | 90,000 | |||||
| Repayment of borrowings | (136,000 | ) | (536,000 | ) | |||
| Dividends paid | (183,853 | ) | (169,917 | ) | |||
| Net cash (used in) / provided by financing activities | $ | (185,862 | ) | $ | (650,596 | ) | |
| Effect of exchange rate changes on cash | $ | (4,631 | ) | $ | 18,272 | ||
| Net increase / (decrease) in cash and cash equivalents | (93,509 | ) | (232,521 | ) | |||
| Cash and cash equivalents at beginning of period | 295,278 | 463,156 | |||||
| Cash and cash equivalents at end of period | $ | 201,769 | $ | 230,635 | |||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles related to cost of sales and are reconciled below:
| Three Months Ended | Nine Months Ended | ||||||||||||||
| March 31, 2022 | March 31, 2021 | March 31, 2022 | March 31, 2021 | ||||||||||||
| Revenue | $ | 864,500 | $ | 768,767 | $ | 2,663,390 | $ | 2,320,722 | |||||||
| GAAP Cost of sales | $ | 373,303 | $ | 321,509 | $ | 1,161,585 | $ | 972,319 | |||||||
| Less: Amortization of acquired intangibles (A) | (10,982 | ) | (10,924 | ) | (33,271 | ) | (34,066 | ) | |||||||
| Less: Restructuring—cost of sales (A) | — | — | — | (5,232 | ) | ||||||||||
| Non-GAAP cost of sales | $ | 362,321 | $ | 310,585 | $ | 1,128,314 | $ | 933,021 | |||||||
| GAAP gross profit | $ | 491,197 | $ | 447,258 | $ | 1,501,805 | $ | 1,348,403 | |||||||
| GAAP gross margin | 56.8 | % | 58.2 | % | 56.4 | % | 58.1 | % | |||||||
| Non-GAAP gross profit | $ | 502,179 | $ | 458,182 | $ | 1,535,076 | $ | 1,387,701 | |||||||
| Non-GAAP gross margin | 58.1 | % | 59.6 | % | 57.6 | % | 59.8 | % | |||||||
The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:
| Three Months Ended | Nine Months Ended | ||||||||||
| March 31, 2022 |
March 31, 2021 |
March 31, 2022 |
March 31, 2021 |
||||||||
| GAAP income from operations | $ | 234,265 | $ | 223,426 | $ | 744,889 | $ | 662,040 | |||
| Amortization of acquired intangibles—cost of sales (A) | 10,982 | 10,924 | 33,271 | 34,066 | |||||||
| Amortization of acquired intangibles—operating expenses (A) | 7,730 | 7,445 | 23,175 | 23,377 | |||||||
| Restructuring—cost of sales (A) | — | — | — | 5,232 | |||||||
| Restructuring—operating expenses (A) | — | — | — | 8,673 | |||||||
| Non-GAAP income from operations | $ | 252,977 | $ | 241,795 | $ | 801,335 | $ | 733,388 | |||
Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)
The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:
| Three Months Ended | Nine Months Ended | ||||||||||||
| March 31, 2022 |
March 31, 2021 |
March 31, 2022 |
March 31, 2021 |
||||||||||
| GAAP net income (loss) | $ | 179,012 | $ | (78,481 | ) | $ | 584,376 | $ | 279,405 | ||||
| Amortization of acquired intangibles—cost of sales, net of tax(A) | 8,374 | 8,395 | 25,373 | 26,136 | |||||||||
| Amortization of acquired intangibles—operating expenses, net of tax(A) | 5,894 | 5,721 | 17,673 | 17,936 | |||||||||
| Reserve for disputed tax position(A) | — | 254,776 | 4,111 | 254,776 | |||||||||
| Restructuring—cost of sales, net of tax(A) | — | — | — | 4,663 | |||||||||
| Restructuring—operating expenses, net of tax(A) | — | — | — | 7,730 | |||||||||
| (Gain) loss on equity investments(A) | — | — | — | (8,476 | ) | ||||||||
| Non-GAAP net income(A) | $ | 193,280 | $ | 190,411 | $ | 631,533 | $ | 582,170 | |||||
| GAAP diluted shares outstanding | 146,962 | 145,513 | 147,034 | 146,394 | |||||||||
| Anti-dilutive shares excluded from GAAP | — | 858 | — | — | |||||||||
| Non-GAAP diluted shares outstanding | 146,962 | 146,371 | 147,034 | 146,394 | |||||||||
| GAAP diluted earnings (loss) per share | $ | 1.22 | $ | (0.54 | ) | $ | 3.97 | $ | 1.91 | ||||
| Non-GAAP diluted earnings per share(A) | $ | 1.32 | $ | 1.30 | $ | 4.30 | $ | 3.98 | |||||
(A) ResMed adjusts for the impact of the amortization of acquired intangibles, reserve for disputed tax positions, restructuring expenses and the (gain) loss on equity investments from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
ResMed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. ResMed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. ResMed believes this information provides investors better insight when evaluating ResMed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-
Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)
| Three Months Ended | |||||||||||
| March 31, 2022 |
(A) | March 31, 2021 |
(A) | % Change | Constant Currency (B) |
||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 250.8 | $ | 192.9 | 30 | % | |||||
| Masks and other | 224.7 | 210.0 | 7 | ||||||||
| Total Sleep and Respiratory Care | $ | 475.4 | $ | 402.9 | 18 | ||||||
| Software as a Service | 101.1 | 93.8 | 8 | ||||||||
| Total | $ | 576.6 | $ | 496.7 | 16 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 182.3 | $ | 172.8 | 5 | % | 10 | % | |||
| Masks and other | 105.6 | 99.2 | 6 | 13 | |||||||
| Total Sleep and Respiratory Care | $ | 287.9 | $ | 272.1 | 6 | 11 | |||||
| Global revenue | |||||||||||
| Devices | $ | 433.1 | $ | 365.7 | 18 | % | 21 | % | |||
| Masks and other | 330.3 | 309.2 | 7 | 9 | |||||||
| Total Sleep and Respiratory Care | $ | 763.4 | $ | 674.9 | 13 | 15 | |||||
| Software as a Service | 101.1 | 93.8 | 8 | 8 | |||||||
| Total | $ | 864.5 | $ | 768.8 | 12 | 14 | |||||
| Nine Months Ended | |||||||||||
| March 31, 2022 |
(A) | March 31, 2021 |
(A) | % Change |
Constant Currency (B) |
||||||
| U.S., Canada, and Latin America | |||||||||||
| Devices | $ | 771.5 | $ | 595.3 | 30 | % | |||||
| Masks and other | 681.8 | 637.5 | 7 | ||||||||
| Total Sleep and Respiratory Care | $ | 1,453.3 | $ | 1,232.8 | 18 | ||||||
| Software as a Service | 297.7 | 277.8 | 7 | ||||||||
| Total | $ | 1,751.0 | $ | 1,510.6 | 16 | ||||||
| Combined Europe, Asia, and other markets | |||||||||||
| Devices | $ | 608.3 | $ | 536.9 | 13 | % | 15 | % | |||
| Masks and other | 304.2 | 273.3 | 11 | 14 | |||||||
| Total Sleep and Respiratory Care | $ | 912.4 | $ | 810.1 | 13 | 15 | |||||
| Global revenue | |||||||||||
| Devices | $ | 1,379.7 | $ | 1,132.1 | 22 | % | 23 | % | |||
| Masks and other | 986.0 | 910.8 | 8 | 9 | |||||||
| Total Sleep and Respiratory Care | $ | 2,365.7 | $ | 2,042.9 | 16 | 16 | |||||
| Software as a Service | 297.7 | 277.8 | 7 | 7 | |||||||
| Total | $ | 2,663.4 | $ | 2,320.7 | 15 | 15 | |||||
(A) Totals and subtotals may not add due to rounding.
(B) In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
| For investors | For media |
| Amy Wakeham | Jayme Rubenstein |
| +1 858-836-5000 | +1 858-836-6798 |
| investorrelations@resmed.com | news@resmed.com |